Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 165
interventional 103
Observational 59
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 46
Biological 37
Drug|placebo 6
Genetic 5
Other 3
Behavioral 1
Device 1
Dietary Supplement 1
Drug|Genetic 1
Drug|Other 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 12
United Kingdom 6
China 4
France 3
NA 3
India 2
Spain 2
United States|Australia 2
United States|Bulgaria|Russian Federation|Switzerland|United Kingdom 2
Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|India|Ireland|Italy|Japan|Poland|Romania|Russian Federation|Sweden|Taiwan|Ukraine|United Kingdom 1
Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine 1
Armenia|Georgia|Poland|Russian Federation|South Africa 1
Australia|Austria|Canada|Czech Republic|France|Germany|Israel|Italy|Russian Federation|Spain 1
Austria|Denmark|Germany|Italy|Malaysia|South Africa|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
Austria|France|Germany|Hungary|Israel|Italy|Spain|Turkey 1
Austria|France|Germany|Israel|Italy|Spain 1
Belgium 1
Brazil 1
Bulgaria 1
Bulgaria|Canada|Croatia|Korea, Republic of|Malaysia|Mexico|Poland|Singapore|Turkey 1
Bulgaria|Germany|Japan|Ukraine|United Kingdom 1
Bulgaria|Israel 1
Bulgaria|Russian Federation 1
Canada 1
Chile|Argentina|Bulgaria|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
Colombia|Czechia|Japan|Poland|Romania|Chile|Argentina|Brazil|Bulgaria|Russian Federation|Spain|Sweden|Ukraine|United Kingdom 1
Denmark|Germany|Netherlands 1
France|Germany|Israel 1
France|Hungary|Israel|Poland|Spain|Turkey|United Kingdom 1
Georgia|Moldova, Republic of|United Kingdom 1
Germany|Greece|Italy|Spain|United Kingdom 1
Germany|Japan|Spain 1
India|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
Israel 1
Korea, Republic of 1
Moldova, Republic of|South Africa|Ukraine 1
Netherlands 1
Poland|Romania|Russian Federation 1
Poland|South Africa|United Kingdom 1
Poland|Ukraine 1
Poland|United Kingdom 1
South Africa 1
Spain|Sweden|United States|Austria|Canada|Croatia|Denmark|Greece|Israel|Italy|Japan|Malaysia|Ukraine|United Kingdom 1
United States|Algeria|Argentina|Australia|Austria|Canada|France|Germany|Israel|Italy|Japan|Malaysia|Netherlands|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Brazil|Bulgaria|France|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Turkey 1
United States|Argentina|Brazil|Canada|Croatia|France|Hungary|Israel|Italy|Japan|Malaysia|Poland|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|France|Germany|Israel|Italy|Japan|Malaysia|Philippines|South Africa|Spain 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Ireland|Italy|Japan|Netherlands|Poland|South Africa|Sweden|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Italy|Japan|Poland|Russian Federation|South Africa|Sweden|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Saudi Arabia|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Denmark|France|Germany|Ireland|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Chile|China|Colombia|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Romania|Russian Federation|Singapore|South Africa|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|China|France|Germany|India|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|Greece|Japan|Saudi Arabia|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|China|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Ireland|Netherlands|South Africa|United Kingdom 1
United States|Austria|Brazil|Croatia|Greece|Hungary|Italy|Japan|Malaysia|Poland|Puerto Rico|Romania|Russian Federation|Serbia|South Africa|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|Bulgaria|France|Germany|Israel|Italy|Japan|Russian Federation|Spain 1
United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Belarus|Bulgaria|Georgia|Israel|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
United States|Belgium|Denmark|Germany|Ireland|Italy|Netherlands|Sweden|United Kingdom 1
United States|Brazil|Bulgaria|Croatia|Japan|New Zealand|Poland|Romania|Russian Federation|Ukraine 1
United States|Brazil|Canada|Croatia|France|Germany|Italy|Japan|Malaysia|Taiwan|United Kingdom 1
United States|Brazil|Former Serbia and Montenegro|France|Japan|Malaysia|Serbia|South Africa|Sweden|Turkey|United Kingdom 1
United States|Bulgaria|Hong Kong|India|Japan|Korea, Republic of|Russian Federation|Spain|Taiwan|Turkey 1
United States|Canada|Croatia|Hungary|Italy|Romania|Russian Federation|Serbia|Spain 1
United States|Canada|France|Germany|Hungary|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Russian Federation|South Africa|Thailand|Turkey|United Kingdom 1
United States|Denmark|France|Germany|Japan|Spain|Sweden|United Kingdom 1
United States|Denmark|France|United Kingdom 1
United States|France|India|Israel|Italy|Poland|United Kingdom 1
United States|Germany|Switzerland 1
United States|Greece|Japan|Malaysia|Romania|Serbia|Thailand 1
United States|Italy|United Kingdom 1
United States|Japan|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Ukraine 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 20
2 2
3 6
4 3
5 4
6 4
7 8
8 3
9 1
10 3
11 2
12 1
14 3
15 4
16 3
17 5
18 2
19 2
20 2
22 1
23 1
24 1
25 2
30 1
32 1
34 1
37 2
39 1
41 1
42 2
43 1
45 1
49 2
51 1
58 1
61 2
64 3

Phase

Phase Study_Count
Phase 3 36
Phase 1 26
Phase 4 12
Phase 2 11
Phase 1/Phase 2 8
N/A 5
Phase 2/Phase 3 5

Number of Arms

Number_of_Arms Count_of_Studies
1 43
2 29
3 13
4 4
5 1
6 2
9 1
10 1
NA 9

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3.0 6.00000 3.000 3.00000 10.0 13.00000 1.00000
1st Qu. 14.0 12.00000 15.250 12.00000 23.0 27.75000 13.75000
Median 20.0 16.00000 24.000 19.00000 50.0 53.00000 27.50000
Mean 132.4 20.38462 24.625 19.09091 44.6 65.03333 32.83333
3rd Qu. 25.0 27.25000 31.750 23.00000 63.0 83.00000 45.75000
Max. 600.0 52.00000 52.000 51.00000 77.0 250.00000 70.00000

Trial Group Type

group_type Group_Count
Experimental 164
Active Comparator 16
NA 9
Other 8
Placebo Comparator 4

Intervention Model

intervention_model Study_Count
Single Group Assignment 50
Parallel Assignment 23
Crossover Assignment 14
NA 8
Sequential Assignment 7
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 85
Other 5
NA 4
Prevention 3
Basic Science 2
Diagnostic 2
Screening 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 15
Japan 5
NA 4
France 3
Canada 2
Korea, Republic of 2
United Kingdom 2
Algeria|Austria|Belgium|Czech Republic|France|Germany|Italy|Netherlands|Poland|Portugal|Saudi Arabia|South Africa|Sweden|Turkey|United Kingdom|Venezuela 1
Algeria|Morocco|Oman|Saudi Arabia|United Arab Emirates 1
Argentina|Austria|Belgium|France|Germany|Hungary|Iran, Islamic Republic of|Ireland|Italy|Poland|Portugal|Slovakia|Sweden|United Kingdom 1
Austria|Belgium|France|Germany|Italy|Netherlands|Portugal|Spain|Sweden|United Kingdom 1
Austria|Canada|Germany|Norway|Portugal 1
Austria|Germany 1
Belgium 1
Belgium|France|Germany|Italy|Spain|Sweden|United Kingdom 1
Brazil 1
Brazil|Canada 1
Canada|Spain|United Kingdom 1
Denmark|Finland|Sweden 1
Denmark|Japan 1
Ecuador 1
Germany 1
Greece|Ireland|Italy|Norway|Saudi Arabia|Sweden|United Arab Emirates|United Kingdom 1
India|Morocco|Oman|South Africa 1
Netherlands|United Kingdom 1
Spain 1
United States|Algeria|Australia|Austria|Bulgaria|Canada|Croatia|Finland|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Canada|Croatia|Czech Republic|France|Germany|Ireland|Italy|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Germany|Israel|Italy|Japan|Netherlands|Sweden|Taiwan 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Austria|France|Germany|Italy|Spain 1
United States|Puerto Rico 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 25
2 3
3 1
4 3
5 6
9 1
11 1
12 2
14 2
16 1
17 2
18 1
19 1
21 2
22 2
23 1
25 1
27 1
38 1
91 1
136 1

Enrollment Metrics

Measure Observational
Min 4.0000
1st Qu 37.5000
Median 86.0000
Mean 252.2034
3rd Qu 266.0000
Max 2300.0000

Observation Model

observational_model Study_Count
Cohort 41
Case-Only 6
NA 6
Ecologic or Community 3
Other 3

Time Perspective

time_perspective Study_Count
Prospective 33
Retrospective 16
Cross-Sectional 7
NA 2
Other 1

Registries

Studies by Country

Country Study_Count
Canada 1
Germany 1
United States 1

Sites per Study

Site_count Study_Count
1 2
38 1

Enrollment Metrics

Measure Registries
Min 66
1st Qu 133
Median 200
Mean 182
3rd Qu 240
Max 280

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
4 Years 1
5 Years 1
7 Days 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03995784 Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT03995784 Completed Catalyst Biosciences 2020-02-28
NCT03407651 Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B https://ClinicalTrials.gov/show/NCT03407651 Completed Catalyst Biosciences 2019-03-15
NCT03369444 A Factor IX Gene Therapy Study (FIX-GT) https://ClinicalTrials.gov/show/NCT03369444 Recruiting University College, London 2021-01-01
NCT03307980 Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B https://ClinicalTrials.gov/show/NCT03307980 Recruiting Pfizer 2026-10-06
NCT03196284 A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT03196284 Completed Novo Nordisk A/S 2018-09-19
NCT03186677 Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT03186677 Completed ISU Abxis Co., Ltd. 2018-10-10
NCT03075670 A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT03075670 Completed Novo Nordisk A/S 2017-12-08
NCT02695160 Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02695160 Active, not recruiting Sangamo Therapeutics 2021-01-31
NCT02571569 A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors https://ClinicalTrials.gov/show/NCT02571569 Completed Bayer 2018-07-09
NCT02554773 An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B https://ClinicalTrials.gov/show/NCT02554773 Active, not recruiting Sanofi 2023-02-28
NCT02541942 Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adeptâ„¢2 Trial https://ClinicalTrials.gov/show/NCT02541942 Completed Novo Nordisk A/S 2016-04-15
NCT02484092 A Gene Therapy Study for Hemophilia B https://ClinicalTrials.gov/show/NCT02484092 Completed Pfizer 2019-04-08
NCT02418793 A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B https://ClinicalTrials.gov/show/NCT02418793 Completed OPKO Health, Inc. 2018-09-30
NCT02396342 Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02396342 Active, not recruiting UniQure Biopharma B.V. 2021-05-31
NCT02336178 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China https://ClinicalTrials.gov/show/NCT02336178 Completed Pfizer 2016-07-31
NCT02263469 A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years https://ClinicalTrials.gov/show/NCT02263469 Completed Bio Products Laboratory 2006-07-31
NCT02263456 A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B https://ClinicalTrials.gov/show/NCT02263456 Completed Bio Products Laboratory 2001-09-30
NCT02250573 An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery https://ClinicalTrials.gov/show/NCT02250573 Completed Bio Products Laboratory 2006-04-30
NCT02250560 A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery. https://ClinicalTrials.gov/show/NCT02250560 Completed Bio Products Laboratory 2003-11-30
NCT02234310 Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02234310 Completed Bioverativ Therapeutics Inc. 2019-08-20
NCT02231944 An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients https://ClinicalTrials.gov/show/NCT02231944 Completed Bio Products Laboratory 2003-10-31
NCT02213250 An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT02213250 Completed Pfizer 2015-04-30
NCT02141074 Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT02141074 Recruiting Novo Nordisk A/S 2022-10-30
NCT01288391 Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients https://ClinicalTrials.gov/show/NCT01288391 Completed Novo Nordisk A/S 2011-07-31
NCT01286779 BAX 326 (rFIX) Continuation Study https://ClinicalTrials.gov/show/NCT01286779 Completed Shire 2017-06-29
NCT01272206 Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT01272206 Completed Novo Nordisk A/S 2011-03-31
NCT02035605 A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients https://ClinicalTrials.gov/show/NCT02035605 Completed Alnylam Pharmaceuticals 2017-07-20
NCT02020369 Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT02020369 Completed rEVO Biologics 2015-07-31
NCT01949792 A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors https://ClinicalTrials.gov/show/NCT01949792 Completed Novo Nordisk A/S 2013-11-30
NCT01921855 Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors https://ClinicalTrials.gov/show/NCT01921855 Completed Bayer 2009-12-31
NCT01757405 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen https://ClinicalTrials.gov/show/NCT01757405 Completed Shire 2014-11-11
NCT01748201 Viscosupplementation in Patients With Hemophilic Arthropathy https://ClinicalTrials.gov/show/NCT01748201 Completed University of Sao Paulo General Hospital 2013-03-31
NCT01687608 Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B https://ClinicalTrials.gov/show/NCT01687608 Active, not recruiting Shire 2030-10-28
NCT01662531 A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B https://ClinicalTrials.gov/show/NCT01662531 Completed CSL Behring 2014-10-31
NCT01625390 A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 https://ClinicalTrials.gov/show/NCT01625390 Completed Bayer 2014-03-31
NCT01563471 Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01563471 Completed Novo Nordisk A/S 2002-07-31
NCT01562587 Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State https://ClinicalTrials.gov/show/NCT01562587 Completed Novo Nordisk A/S 2003-05-31
NCT01561924 Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography https://ClinicalTrials.gov/show/NCT01561924 Completed Novo Nordisk A/S 2006-05-31
NCT01561417 Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT01561417 Completed Novo Nordisk A/S 2006-09-30
NCT01561391 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery https://ClinicalTrials.gov/show/NCT01561391 Completed Novo Nordisk A/S 2004-05-31
NCT01555749 Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects https://ClinicalTrials.gov/show/NCT01555749 Completed Novo Nordisk A/S 2012-05-08
NCT01507896 BAX 326 Surgery Study in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT01507896 Completed Shire 2014-05-15
NCT01496274 A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT01496274 Completed CSL Behring 2014-07-31
NCT01488994 BAX 326 Pediatric Study https://ClinicalTrials.gov/show/NCT01488994 Completed Shire 2013-05-14
NCT01467427 Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. https://ClinicalTrials.gov/show/NCT01467427 Active, not recruiting Novo Nordisk A/S 2014-03-30
NCT01440946 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01440946 Completed Bioverativ Therapeutics Inc. 2014-11-30
NCT01425723 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01425723 Completed Bioverativ Therapeutics Inc. 2017-10-31
NCT01395810 Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 https://ClinicalTrials.gov/show/NCT01395810 Completed Novo Nordisk A/S 2014-03-30
NCT01392547 Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors https://ClinicalTrials.gov/show/NCT01392547 Completed Novo Nordisk A/S 2012-08-31
NCT01386528 Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B https://ClinicalTrials.gov/show/NCT01386528 Completed Novo Nordisk A/S 2013-12-01
NCT01361126 A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT01361126 Completed CSL Behring 2012-06-30
NCT01335061 Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT01335061 Completed Pfizer 2014-04-30
NCT01333111 Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients https://ClinicalTrials.gov/show/NCT01333111 Completed Novo Nordisk A/S 2013-03-31
NCT04394286 A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects https://ClinicalTrials.gov/show/NCT04394286 Recruiting Shire 2024-03-16
NCT04286412 Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B https://ClinicalTrials.gov/show/NCT04286412 Recruiting Pfizer 2020-11-05
NCT04135300 Gene Therapy for Chinese Hemophilia B https://ClinicalTrials.gov/show/NCT04135300 Recruiting Institute of Hematology & Blood Diseases Hospital 2021-06-30
NCT04073498 The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) https://ClinicalTrials.gov/show/NCT04073498 Recruiting ApcinteX Ltd 2021-04-30
NCT04072237 Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia https://ClinicalTrials.gov/show/NCT04072237 Active, not recruiting Catalyst Biosciences 2020-04-30
NCT03861273 A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT03861273 Recruiting Pfizer 2021-11-26
NCT03855280 Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT03855280 Recruiting Medexus Pharma, Inc. 2021-08-01
NCT03641703 A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy https://ClinicalTrials.gov/show/NCT03641703 Recruiting Freeline Therapeutics 2035-12-31
NCT03615053 Personalized Medicine for Canadians With Hemophilia https://ClinicalTrials.gov/show/NCT03615053 Recruiting McMaster University 2021-09-30
NCT03587116 Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) https://ClinicalTrials.gov/show/NCT03587116 Recruiting Pfizer 2021-09-24
NCT03569891 HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients https://ClinicalTrials.gov/show/NCT03569891 Active, not recruiting UniQure Biopharma B.V. 2020-09-30
NCT03507582 Virtual Reality for Hemophilia https://ClinicalTrials.gov/show/NCT03507582 Completed Nationwide Children’s Hospital 2016-12-28
NCT03489291 Dose Confirmation Trial of AAV5-hFIXco-Padua https://ClinicalTrials.gov/show/NCT03489291 Active, not recruiting UniQure Biopharma B.V. 2018-10-30
NCT03481946 A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia https://ClinicalTrials.gov/show/NCT03481946 Completed Bayer 2018-10-17
NCT03417245 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors https://ClinicalTrials.gov/show/NCT03417245 Active, not recruiting Sanofi 2021-04-30
NCT03417102 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT03417102 Active, not recruiting Sanofi 2020-12-31
NCT01233440 Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT01233440 Completed CSL Behring 2011-07-31
NCT01228669 Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B https://ClinicalTrials.gov/show/NCT01228669 Completed Novo Nordisk A/S 2012-09-10
NCT01174446 Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT01174446 Completed Shire 2012-05-03
NCT01128881 IMMUNINE Pre-Treatment Study https://ClinicalTrials.gov/show/NCT01128881 Completed Shire 2012-08-31
NCT01090206 Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT01090206 Completed Virginia Commonwealth University 2013-03-31
NCT01027364 Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B https://ClinicalTrials.gov/show/NCT01027364 Completed Bioverativ Therapeutics Inc. 2012-07-31
NCT00979238 Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B https://ClinicalTrials.gov/show/NCT00979238 Active, not recruiting St. Jude Children’s Research Hospital 2032-06-12
NCT00956345 Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT00956345 Completed Novo Nordisk A/S 2010-07-31
NCT00951873 A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT00951873 Completed Novo Nordisk A/S 2010-04-30
NCT00951405 Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors https://ClinicalTrials.gov/show/NCT00951405 Completed Novo Nordisk A/S 2011-03-29
NCT00922792 Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B https://ClinicalTrials.gov/show/NCT00922792 Completed Novo Nordisk A/S 2009-09-30
NCT00866606 Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects https://ClinicalTrials.gov/show/NCT00866606 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-12-31
NCT00851721 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor https://ClinicalTrials.gov/show/NCT00851721 Completed Shire 2012-10-31
NCT01562457 Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State https://ClinicalTrials.gov/show/NCT01562457 Completed Novo Nordisk A/S 2006-04-30
NCT03938792 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B https://ClinicalTrials.gov/show/NCT03938792 Recruiting Pfizer 2023-04-27
NCT02053792 A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT02053792 Active, not recruiting CSL Behring 2021-09-30
NCT03091751 Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B https://ClinicalTrials.gov/show/NCT03091751 Completed Grifols Biologicals, LLC 2009-10-31
NCT03565237 RIXUBIS PMS India (RIXUBIS PMS) https://ClinicalTrials.gov/show/NCT03565237 Recruiting Shire 2021-04-21
NCT00768287 Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT00768287 Completed Aptevo Therapeutics 2013-03-31
NCT00749476 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX https://ClinicalTrials.gov/show/NCT00749476 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-01-31
NCT00716716 Phase I/IIa Study of FIXFc in Hemophilia B Patients https://ClinicalTrials.gov/show/NCT00716716 Completed Bioverativ Therapeutics Inc. 2009-10-31
NCT00638001 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy https://ClinicalTrials.gov/show/NCT00638001 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2012-03-31
NCT00581126 Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00581126 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00571584 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors https://ClinicalTrials.gov/show/NCT00571584 Completed Novo Nordisk A/S 2004-03-31
NCT00486278 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds https://ClinicalTrials.gov/show/NCT00486278 Completed Novo Nordisk A/S 2010-06-30
NCT00364182 Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00364182 Completed Pfizer 2010-10-31
NCT00212459 The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs https://ClinicalTrials.gov/show/NCT00212459 Completed New York Presbyterian Hospital 2006-02-28
NCT00139828 Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) https://ClinicalTrials.gov/show/NCT00139828 Completed Sanquin Plasma Products BV NA
NCT00108797 Trial of NovoSeven® in Haemophilia - Joint Bleeds https://ClinicalTrials.gov/show/NCT00108797 Completed Novo Nordisk A/S 2006-02-28
NCT00108758 Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia https://ClinicalTrials.gov/show/NCT00108758 Completed Novo Nordisk A/S 2005-11-30
NCT00093210 Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00093210 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00093171 Study Evaluating rFIX; BeneFIX® in Hemophilia B https://ClinicalTrials.gov/show/NCT00093171 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-05-31
NCT00037557 Study Evaluating rFIX; BeneFIX in Severe Hemophilia B https://ClinicalTrials.gov/show/NCT00037557 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00004801 Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency https://ClinicalTrials.gov/show/NCT00004801 Completed Office of Rare Diseases (ORD) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03358836 Joint Health Study https://ClinicalTrials.gov/show/NCT03358836 Active, not recruiting Bloodworks 2027-12-31
NCT03276130 Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B https://ClinicalTrials.gov/show/NCT03276130 Recruiting Swedish Orphan Biovitrum 2019-12-31
NCT03185897 Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia https://ClinicalTrials.gov/show/NCT03185897 Active, not recruiting Shire 2022-04-30
NCT03054389 Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews https://ClinicalTrials.gov/show/NCT03054389 Completed Shire 2017-06-06
NCT02937831 RIXUBIS Drug Use-Result Survey (Japan) https://ClinicalTrials.gov/show/NCT02937831 Recruiting Shire 2021-04-30
NCT02922231 Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea https://ClinicalTrials.gov/show/NCT02922231 Completed Shire 2019-04-04
NCT00835068 Post Marketing Observational Study of Reformulated BeneFIX https://ClinicalTrials.gov/show/NCT00835068 Completed Pfizer 2013-10-31
NCT02807753 The Hemophilia Ultrasound Project https://ClinicalTrials.gov/show/NCT02807753 Recruiting University of Miami 2021-07-31
NCT02740413 Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study https://ClinicalTrials.gov/show/NCT02740413 Completed Pfizer 2017-12-31
NCT02634918 Ultrasonography in Hemophilic Joint Disease and Serum Markers https://ClinicalTrials.gov/show/NCT02634918 Completed Northwell Health 2019-08-31
NCT02502409 Natural History Study of Factor IX Treatment and Complications https://ClinicalTrials.gov/show/NCT02502409 Active, not recruiting Skane University Hospital 2019-06-30
NCT02300519 Thrombin Generation Numerical Models Validation in Haemophilic Case https://ClinicalTrials.gov/show/NCT02300519 Completed Centre Hospitalier Universitaire de Saint Etienne 2015-07-31
NCT02241694 To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives https://ClinicalTrials.gov/show/NCT02241694 Completed Novo Nordisk A/S 2015-07-31
NCT02190149 Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS https://ClinicalTrials.gov/show/NCT02190149 Completed Shire 2016-03-31
NCT02049099 A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care https://ClinicalTrials.gov/show/NCT02049099 Completed Swedish Orphan Biovitrum 2015-09-30
NCT01988532 Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia https://ClinicalTrials.gov/show/NCT01988532 Completed Novo Nordisk A/S 2014-10-31
NCT01959555 Project to Update the Study of Congenital Haemophilia in Spain https://ClinicalTrials.gov/show/NCT01959555 Completed Novo Nordisk A/S 2014-12-31
NCT01830712 A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors https://ClinicalTrials.gov/show/NCT01830712 Completed Novo Nordisk A/S 2011-08-31
NCT01589848 Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador https://ClinicalTrials.gov/show/NCT01589848 Completed Universidad del Azuay 2013-06-30
NCT01586936 Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors https://ClinicalTrials.gov/show/NCT01586936 Completed Novo Nordisk A/S 2010-03-09
NCT01579968 Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery https://ClinicalTrials.gov/show/NCT01579968 Completed Novo Nordisk A/S 2010-03-09
NCT01579955 Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice https://ClinicalTrials.gov/show/NCT01579955 Completed Novo Nordisk A/S 2010-03-09
NCT01510418 Socialization of Adult Men With Congenital Hemophilia A or B https://ClinicalTrials.gov/show/NCT01510418 Completed Dana-Farber Cancer Institute 2013-05-31
NCT01503567 Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries https://ClinicalTrials.gov/show/NCT01503567 Completed Novo Nordisk A/S 2012-09-30
NCT01322620 Survey Evaluating the Psychosocial Effects of Living With Haemophilia https://ClinicalTrials.gov/show/NCT01322620 Completed Novo Nordisk A/S 2012-02-29
NCT03875547 Post-marketing Surveillance (Use Result Surveillance) With Refixia® https://ClinicalTrials.gov/show/NCT03875547 Enrolling by invitation Novo Nordisk A/S 2025-09-30
NCT03818529 ATHN 8: PUPs Matter Study https://ClinicalTrials.gov/show/NCT03818529 Recruiting American Thrombosis and Hemostasis Network 2023-03-31
NCT03690336 Adverse Event Data Collection From External Registries on Nonacog Beta Pegol https://ClinicalTrials.gov/show/NCT03690336 Enrolling by invitation Novo Nordisk A/S 2027-10-01
NCT03655340 A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France https://ClinicalTrials.gov/show/NCT03655340 Active, not recruiting Swedish Orphan Biovitrum 2021-09-30
NCT03430154 Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) https://ClinicalTrials.gov/show/NCT03430154 Completed Novo Nordisk A/S 2018-04-29
NCT01234545 Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors https://ClinicalTrials.gov/show/NCT01234545 Completed Novo Nordisk A/S 2012-04-30
NCT01220141 Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B https://ClinicalTrials.gov/show/NCT01220141 Completed Novo Nordisk A/S 2015-03-31
NCT01217255 Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World https://ClinicalTrials.gov/show/NCT01217255 Completed The Hospital for Sick Children 2013-10-31
NCT01154231 BeneFIX Drug Use Results Survey [All-Case Surveillance] https://ClinicalTrials.gov/show/NCT01154231 Completed Pfizer 2014-08-31
NCT00936845 Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study https://ClinicalTrials.gov/show/NCT00936845 Completed Weill Medical College of Cornell University 2010-01-31
NCT00936312 Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study https://ClinicalTrials.gov/show/NCT00936312 Completed Weill Medical College of Cornell University 2011-08-31
NCT00927992 Study Evaluating Liver Transplantation in Haemophilia Patients in Spain https://ClinicalTrials.gov/show/NCT00927992 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2010-06-30
NCT00882778 PROPACT: Retrospective Prophylaxis Patient Case Collection https://ClinicalTrials.gov/show/NCT00882778 Completed Novo Nordisk A/S 2010-05-31
NCT00853086 Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database https://ClinicalTrials.gov/show/NCT00853086 Completed Novo Nordisk A/S 2011-06-30
NCT03901755 An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B https://ClinicalTrials.gov/show/NCT03901755 Recruiting Swedish Orphan Biovitrum 2023-03-31
NCT03660774 A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia https://ClinicalTrials.gov/show/NCT03660774 Completed Novo Nordisk A/S 2019-10-11
NCT03533504 Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability https://ClinicalTrials.gov/show/NCT03533504 Enrolling by invitation McMaster University 2024-06-30
NCT03055611 A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B https://ClinicalTrials.gov/show/NCT03055611 Active, not recruiting Swedish Orphan Biovitrum 2022-04-30
NCT02568202 Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) https://ClinicalTrials.gov/show/NCT02568202 Completed Novo Nordisk A/S 2015-11-30
NCT00824798 Gait Evaluation in Haemophiliac Patients https://ClinicalTrials.gov/show/NCT00824798 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2011-01-31
NCT02938156 UK - EHL Outcomes Registry https://ClinicalTrials.gov/show/NCT02938156 Recruiting Royal Free Hospital NHS Foundation Trust 2019-10-31
NCT02971969 Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B https://ClinicalTrials.gov/show/NCT02971969 Active, not recruiting Ultragenyx Pharmaceutical Inc 2022-02-18
NCT02796222 Factor Product Utilization and Health Outcomes in Patients With Hemophilia https://ClinicalTrials.gov/show/NCT02796222 Recruiting University of British Columbia 2019-12-31
NCT03745924 A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN https://ClinicalTrials.gov/show/NCT03745924 Enrolling by invitation Novo Nordisk A/S 2027-12-15
NCT03741881 A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorerâ„¢6) https://ClinicalTrials.gov/show/NCT03741881 Enrolling by invitation Novo Nordisk A/S 2021-03-17
NCT00714415 Registry For Patients Treated With BeneFix In Usual Care Setting In Germany https://ClinicalTrials.gov/show/NCT00714415 Completed Pfizer 2016-10-31
NCT00710619 Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX https://ClinicalTrials.gov/show/NCT00710619 Completed Novo Nordisk A/S 2009-07-31
NCT00703911 Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors https://ClinicalTrials.gov/show/NCT00703911 Completed Novo Nordisk A/S 2010-07-31
NCT00581438 Study Evaluating Approach to Treatment of Haemophilia A and B in Spain https://ClinicalTrials.gov/show/NCT00581438 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2007-12-31
NCT00515710 LTFU for Gene Transfer Subjects With Hemophilia B https://ClinicalTrials.gov/show/NCT00515710 Completed Spark Therapeutics 2017-12-31
NCT00484185 Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00484185 Completed Pfizer 2012-06-30
NCT00244114 Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients https://ClinicalTrials.gov/show/NCT00244114 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-12-31
NCT00195221 Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B https://ClinicalTrials.gov/show/NCT00195221 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00167973 Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use https://ClinicalTrials.gov/show/NCT00167973 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-06-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02912143 German Pediatric Hemophilia Research Database https://ClinicalTrials.gov/show/NCT02912143 Recruiting Ludwig-Maximilians - University of Munich 2022-01-01
NCT02199717 An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia https://ClinicalTrials.gov/show/NCT02199717 Completed The Hospital for Sick Children 2014-07-31
NCT03619863 ATHN 7: Hemophilia Natural History Study https://ClinicalTrials.gov/show/NCT03619863 Recruiting American Thrombosis and Hemostasis Network 2023-09-30